Clinical Trial Detail

NCT ID NCT02963090
Title Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alliance Foundation Trials, LLC.
Indications

lung small cell carcinoma

Therapies

Pembrolizumab + Topotecan

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.